

Opioid Agonist

Buprenex (buprenorphine) J0592, Sublocade (buprenorphine XR) Q9991, Q9992, Probuphine (buprenorphine implant) J0570 Prior Authorization Request Medicare Part B Form

Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

NEW START - Start Date:				Continuation (within 365 days): Date of last treatment				
	Date Requested							
Requestor Clinic name:						/ Fax		
MEMBER INFORMATION								
*Name: *ID#: *DOB:								
PRESCRIBER INFORMATION								
*Nar	ne:	DMI	D □FNP □DO □NP □PA *Phone:					
*Adc	lress:		*Fax:					
DISPENSING PROVIDER / ADMINISTRATION INFORMATION								
*Name: Phone:								
*Address:Fax:								
PROCEDURE / PRODUCT INFORMATION								
нсі	PC Code	Name of Drug	Dos	e (Wt: kg Ht:)	Frequency	End Date if known	
Chart notes attached. Other important information:								
Diagnosis: ICD10: Description:								
\square Provider attests the diagnosis provided is an FDA-Approved indication for this drug								
CLINICAL INFORMATION								
 New Start or Initial Request: (Clinical documentation required for all requests) Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria. If not, please provide clinical rationale for formulary exception: 								
 Continuation Requests: (Clinical documentation required for all requests) Provider has reviewed the attached "Criteria for Continuation" and attests the member meets ALL required PA Continuation criteria. Patient had an <u>adequate response</u> or <u>significant improvement</u> while on this medication. 								
If not, please provide clinical rationale for continuing this medication:								
ACKNOWLEDGEMENT								
Request By (Signature Required):								

For questions or assistance, please contact Customer Service at 1-877-672-8620, daily, 8am – 8pm (PST) (TTY users should call 1-800-735-2900).



Prior Authorization Group - Opioid Agonists (Mixed) PA

Drug Name(s): BUPRENEX SUBLOCADE PROBUPHINE BUPRENORPHINE XR

Criteria for approval of Prior Authorization Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Drug is being used appropriately per MCG GUIDELINES, CMS recognized compendia, authoritative medical literature, evidence-based guidelines and/or accepted standards of medical practice.
- 3. Used as part of a complete treatment plan that includes counseling and psychosocial support or REMS program
- 4. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria: N/A

Prescriber Restrictions: N/A

Coverage Duration: Approval will be for 12 months

FDA Indications:

Sublocade

• Opioid dependence, Induction of treatment

Buprenex

Pain (Moderate to Severe)

Probuphine

 Opioid dependence, Maintenance treatment in patients with prolonged clinical stability on low to moderate doses of a transmucosal buprenorphine product

Off-Label Uses:

Buprenex

Neonatal Abstinence Syndrome

Age Restrictions: N/A

Other Clinical Considerations: N/A



Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/PFDefaultActionId/evidencexpert.DoIntegratedSearch?navitem=headerLogout

https://careweb.careguidelines.com/ed24/bhg/bhg_05123.htm

https://careweb.careguidelines.com/ed24/bhg/bhg_05124.htm